HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression

B Keith, RS Johnson, MC Simon - Nature Reviews Cancer, 2012 - nature.com
Hypoxia-inducible factors (HIFs) are broadly expressed in human cancers, and HIF1α and
HIF2α were previously suspected to promote tumour progression through largely …

[HTML][HTML] Adverse outcome pathway from activation of the AhR to breast cancer-related death

L Benoit, F Jornod, E Zgheib, C Tomkiewicz… - Environment …, 2022 - Elsevier
Adverse outcome pathways (AOPs) are formalized and structured linear concepts that
connect one molecular initiating event (MIE) to an adverse outcome (AO) via different key …

13C NMR-Based Metabolomics for the Classification of Green Coffee Beans According to Variety and Origin

F Wei, K Furihata, M Koda, F Hu, R Kato… - Journal of Agricultural …, 2012 - ACS Publications
13C NMR-based metabolomics was demonstrated as a useful tool for distinguishing the
species and origins of green coffee bean samples of arabica and robusta from six different …

Hypoxia-inducible aryl hydrocarbon receptor nuclear translocator (ARNT)(HIF-1β): is it a rare exception?

M Mandl, R Depping - Molecular Medicine, 2014 - Springer
The aryl hydrocarbon receptor nuclear translocator (ARNT), also designated as hypoxia-
inducible factor (HIF)-1β, plays a pivotal role in the adaptive responses to (micro-) …

Non-viral nanocarriers for siRNA delivery in breast cancer

J Zhang, X Li, L Huang - Journal of controlled release, 2014 - Elsevier
Breast cancer is the most frequently diagnosed malignancy in American women. While
significant progress has been made in the development of modern diagnostic tools and …

[HTML][HTML] siRNA-based nanocarriers for targeted drug delivery to control breast cancer

S Ashique, B Almohaywi, N Haider, S Yasmin… - Advances in Cancer …, 2022 - Elsevier
Breast cancer is a challenging health issue in women and the second-leading cause of
mortality around world. In this review, we addressed beneficial role of siRNA to control …

Application of genomics, proteomics and metabolomics in drug discovery, development and clinic

C Russell, A Rahman, AR Mohammed - Therapeutic delivery, 2013 - Taylor & Francis
Genomics, proteomics and metabolomics are three areas that are routinely applied
throughout the drug-development process as well as after a product enters the market. This …

Downregulation of ARNT2 promotes tumor growth and predicts poor prognosis in human hepatocellular carcinoma

W Li, Y Liang, B Yang, H Sun… - … of gastroenterology and …, 2015 - Wiley Online Library
Abstract Background and Aim Aryl‐hydrocarbon receptor nuclear translocator 2 (ARNT2) is
a transcriptional regulator and member of the basic helix‐loop‐helix/P er‐ARNT‐SIM …

Changes in chromatin state reveal ARNT2 at a node of a tumorigenic transcription factor signature driving glioblastoma cell aggressiveness

A Bogeas, G Morvan-Dubois, EA El-Habr… - Acta …, 2018 - Springer
Although a growing body of evidence indicates that phenotypic plasticity exhibited by
glioblastoma cells plays a central role in tumor development and post-therapy recurrence …

ARNT2 is downregulated and serves as a potential tumor suppressor gene in non-small cell lung cancer

B Yang, E Yang, H Liao, Z Wang, Z Den, H Ren - Tumor Biology, 2015 - Springer
The present study aims to investigate the expression pattern of aryl hydrocarbon receptor
nuclear translocator 2 (ARNT2) protein and its clinical significance in human non-small cell …